Success Metrics

Clinical Success Rate
68.9%

Based on 51 completed trials

Completion Rate
69%(51/74)
Active Trials
6(6%)
Results Posted
27%(14 trials)
Terminated
23(21%)

Phase Distribution

Ph phase_3
9
8%
Ph phase_2
58
54%
Ph phase_4
2
2%
Ph not_applicable
1
1%
Ph early_phase_1
2
2%
Ph phase_1
34
32%

Phase Distribution

36

Early Stage

58

Mid Stage

11

Late Stage

Phase Distribution106 total trials
Early Phase 1First-in-human
2(1.9%)
Phase 1Safety & dosage
34(32.1%)
Phase 2Efficacy & side effects
58(54.7%)
Phase 3Large-scale testing
9(8.5%)
Phase 4Post-market surveillance
2(1.9%)
N/ANon-phased studies
1(0.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.7%

51 of 84 finished

Non-Completion Rate

39.3%

33 ended early

Currently Active

6

trials recruiting

Total Trials

107

all time

Status Distribution
Active(7)
Completed(51)
Terminated(33)
Other(16)

Detailed Status

Completed51
Terminated23
unknown15
Withdrawn10
Recruiting4
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
107
Active
6
Success Rate
68.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.9%)
Phase 134 (32.1%)
Phase 258 (54.7%)
Phase 39 (8.5%)
Phase 42 (1.9%)
N/A1 (0.9%)

Trials by Status

recruiting44%
terminated2321%
completed5148%
active_not_recruiting22%
suspended11%
unknown1514%
enrolling_by_invitation11%
withdrawn109%

Recent Activity

6 active trials
Showing 5 of 107
recruitingphase_2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT01409161
active_not_recruitingphase_3

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
enrolling_by_invitationphase_1

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

NCT03031249
active_not_recruitingphase_2

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

NCT03503864
recruitingphase_2

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

NCT06933394
View all 107 trials

Clinical Trials (107)

Showing 20 of 107 trialsScroll for more
NCT01409161Phase 2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Recruiting
NCT02339740Phase 3

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Active Not Recruiting
NCT03031249Phase 1

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Enrolling By Invitation
NCT03503864Phase 2

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

Active Not Recruiting
NCT06933394Phase 2

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Recruiting
NCT02688140Phase 3

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Completed
NCT04793919Phase 2

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Recruiting
NCT04996030Phase 1

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Suspended
NCT06088030Phase 2

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Recruiting
NCT03377725Phase 3

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Withdrawn
NCT00551460Phase 2

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Completed
NCT03855371Phase 1

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

Unknown
NCT05497310Phase 1

Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL

Unknown
NCT00866918Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Completed
NCT00482833Phase 3

Phase III Trial in Acute Promyelocytic Leukemia Patients

Completed
NCT03980665Phase 1

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART

Unknown
NCT01014546Phase 1

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Terminated
NCT05297123Phase 1

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Unknown
NCT03751917

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

Unknown
NCT02899169Phase 3

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
107